VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction
CAMPBELL, Calif. , June 11, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S.
View HTML
Toggle Summary VIVUS Reports First Quarter 2018 Financial Results
  VIVUS Reports First Quarter 2018 Financial Results     Company provides business update on PANCREAZE ® acquisition,  new Athyrium debt line and new management Company to host conference call today at 4:30pm ET CAMPBELL, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS ) (the
View HTML
Toggle Summary VIVUS Announces Date of 2018 Annual Meeting
VIVUS Announces Date of 2018 Annual Meeting   CAMPBELL, CA., May 4, 2018 – VIVUS, Inc. (N asdaq : VVUS; the “Company”), a biopharmaceutical company, today announced that the Company will hold its 2018 Annual Meeting of Stockholders (the “2018 Annual Meeting”) on September 7, 2018.
View HTML
Toggle Summary VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE®
Attains key milestone under strategic focus on building a broad portfolio of cash flow-generating products   CAMPBELL, CA., May 1, 2018 – VIVUS, Inc. (N asdaq : VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into a definitive agreement to acquire all product
View HTML
Toggle Summary VIVUS Restructures Debt and Gains Access to New Capital
Athyrium Capital Management partners with VIVUS to support next growth phase   New capital to be used to facilitate the acquisition of PANCREAZE ® (pancrelipase)   CAMPBELL, CA. and NEW YORK, N.Y., May 1, 2018 – VIVUS, Inc. (N asdaq : VVUS; the “Company”), a biopharmaceutical company and Athyrium
View HTML
Toggle Summary VIVUS Strengthens Executive Leadership Team
John Amos, Kenneth Suh and Scott Oehrlein join VIVUS New team brings extensive expertise in cash-flow positive asset acquisition, product portfolio optimization, and enterprise value creation CAMPBELL, CA -- (Marketwired) -- 04/30/18 -- VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical
View HTML
Toggle Summary VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018
CAMPBELL, CA -- (Marketwired) -- 04/25/18 -- VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2018 after the market close on Tuesday, May 8, 2018 . The company will host a conference call beginning at 4:30 p.m.
View HTML
Toggle Summary VIVUS Reports Fourth Quarter 2017 Financial Results
CAMPBELL, CA -- (Marketwired) -- 03/13/18 -- VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for
View HTML
Toggle Summary VIVUS Announces Change in Leadership
Board Member Thomas B. King appointed interim CEO; Seth Fischer steps down as CEO effective December 31, 2017 CAMPBELL, CA -- (Marketwired) -- 12/26/17 -- VIVUS, Inc. (NASDAQ: VVUS) today announced that it has reached agreement with Seth H. Z. Fischer pursuant to which he will step down as chief
View HTML
Toggle Summary VIVUS Reports Third Quarter 2017 Financial Results
CAMPBELL, CA -- (Marketwired) -- 11/07/17 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for
View HTML